Development of an extended action fostemsavir lipid nanoparticle

Farhana Islam; Srijanee Das; Md Ashaduzzaman; Brady Sillman; Pravin Yeapuri; Mohammad Ullah Nayan; David Oupický; Howard E. Gendelman; Bhavesh D. Kevadiya

doi:10.1038/s42003-024-06589-5

Development of an extended action fostemsavir lipid nanoparticle

Farhana Islam, Srijanee Das, Md Ashaduzzaman, Brady Sillman, Pravin Yeapuri, Mohammad Ullah Nayan, David Oupický, Howard E. Gendelman, Bhavesh D. Kevadiya

Research output: Contribution to journal › Article › peer-review

Abstract

An extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR formulation establishes a drug depot in monocyte-derived macrophages that extend the drug’s plasma residence time. The LNP’s physicochemical properties improve FTR’s antiretroviral activities, which are linked to the drug’s ability to withstand fluid flow forces and levels of drug cellular internalization. Each is, in measure, dependent on PEGylated lipid composition and flow rate ratios affecting the size, polydispersity, shape, zeta potential, stability, biodistribution, and antiretroviral efficacy. The FTR LNP physicochemical properties enable the drug-particle’s extended actions.

Original language	English (US)
Article number	917
Journal	Communications biology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s42003-024-06589-5
State	Published - Dec 2024

ASJC Scopus subject areas

Medicine (miscellaneous)
General Biochemistry, Genetics and Molecular Biology
General Agricultural and Biological Sciences

Access to Document

10.1038/s42003-024-06589-5

Cite this

@article{d13c6247f3a64bfe875bc350b642251f,

title = "Development of an extended action fostemsavir lipid nanoparticle",

abstract = "An extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR formulation establishes a drug depot in monocyte-derived macrophages that extend the drug{\textquoteright}s plasma residence time. The LNP{\textquoteright}s physicochemical properties improve FTR{\textquoteright}s antiretroviral activities, which are linked to the drug{\textquoteright}s ability to withstand fluid flow forces and levels of drug cellular internalization. Each is, in measure, dependent on PEGylated lipid composition and flow rate ratios affecting the size, polydispersity, shape, zeta potential, stability, biodistribution, and antiretroviral efficacy. The FTR LNP physicochemical properties enable the drug-particle{\textquoteright}s extended actions.",

author = "Farhana Islam and Srijanee Das and Md Ashaduzzaman and Brady Sillman and Pravin Yeapuri and Nayan, {Mohammad Ullah} and David Oupick{\'y} and Gendelman, {Howard E.} and Kevadiya, {Bhavesh D.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1038/s42003-024-06589-5",

language = "English (US)",

volume = "7",

journal = "Communications biology",

issn = "2399-3642",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Development of an extended action fostemsavir lipid nanoparticle

AU - Islam, Farhana

AU - Das, Srijanee

AU - Ashaduzzaman, Md

AU - Sillman, Brady

AU - Yeapuri, Pravin

AU - Nayan, Mohammad Ullah

AU - Oupický, David

AU - Gendelman, Howard E.

AU - Kevadiya, Bhavesh D.

PY - 2024/12

Y1 - 2024/12

N2 - An extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR formulation establishes a drug depot in monocyte-derived macrophages that extend the drug’s plasma residence time. The LNP’s physicochemical properties improve FTR’s antiretroviral activities, which are linked to the drug’s ability to withstand fluid flow forces and levels of drug cellular internalization. Each is, in measure, dependent on PEGylated lipid composition and flow rate ratios affecting the size, polydispersity, shape, zeta potential, stability, biodistribution, and antiretroviral efficacy. The FTR LNP physicochemical properties enable the drug-particle’s extended actions.

AB - An extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR formulation establishes a drug depot in monocyte-derived macrophages that extend the drug’s plasma residence time. The LNP’s physicochemical properties improve FTR’s antiretroviral activities, which are linked to the drug’s ability to withstand fluid flow forces and levels of drug cellular internalization. Each is, in measure, dependent on PEGylated lipid composition and flow rate ratios affecting the size, polydispersity, shape, zeta potential, stability, biodistribution, and antiretroviral efficacy. The FTR LNP physicochemical properties enable the drug-particle’s extended actions.

UR - http://www.scopus.com/inward/record.url?scp=85200038563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85200038563&partnerID=8YFLogxK

U2 - 10.1038/s42003-024-06589-5

DO - 10.1038/s42003-024-06589-5

M3 - Article

C2 - 39080401

AN - SCOPUS:85200038563

SN - 2399-3642

VL - 7

JO - Communications biology

JF - Communications biology

IS - 1

M1 - 917

ER -

Development of an extended action fostemsavir lipid nanoparticle

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this